Turing, one of the world's fastest-growing AGI infrastructure companies, announced today that it has secured $111 million in committed capital for its Series E financing at a valuation of $2.2 billion ...

GAITHERSBURG, Md., March 19, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today announced that it has completed the sale of its Baltimore-Bayview drug substance manufacturing ...

BANGALORE, India, March 10, 2025 /PRNewswire/ -- Syngene International Limited ('Syngene'), a global contract research, development, and manufacturing organization ...

GAITHERSBURG, Md., March 10, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today announced that it has entered into an agreement to sell its Baltimore-Bayview drug substance ...

Syngene International, the contract research wing of Biocon Group, has acquired its first manufacturing facility in the US from Emergent Manufacturing Operations Baltimore. The pharma player has ...

Syngene is paying $36.5 million to acquire Emergent's shuttered biologics facility in the Bayview neighborhood of Baltimore, the Indian drugmaker said (PDF) Monday.

India-based Syngene International on Monday said it will invest around $50 million on a biologics facility in the Baltimore area, expanding its global manufacturing footprint as companies look to ...

(MENAFN- PR Newswire) The state-of-the-art biologics facility, acquired by Syngene USA Inc., a wholly owned subsidiary of Syngene, from Emergent manufacturing Operations Baltimore, LLC (a ...

Bangalore, March 10, 2025: Syngene International Limited (‘Syngene’), a global contract research, development, and manufacturing organization (CRDMO), today announced the acquisition of its first ...

Expected to enhance global innovator flexibility with biologics drug substance facility in Baltimore BANGALORE, India, March 10, 2025 /PRNewswire/ -- Syngene International Limited ('Syngene'), a ...

As of March 10, Syngene International Ltd. announces its first biologics facility purchase in the USA. The site houses several monoclonal antibody (mAbs) production lines. Syngene USA Inc., a ...

India's Syngene International on Monday said it has acquired its first biologics facility in the United States from Emergent Manufacturing Operations Baltimore, a unit of Emergent BioSolutions, for ...